EGFR and esophageal squamous cell carcinoma: Gefitinib is a well‐known orally active, reversible and selective EGFR inhibitor applied for ESCC treatment in clinic.7, 8 However, the resistance of gefitinib has become a new challenge for ESCC treatment with unclear mechanism.9